Back to Homepage

Heralding a New Era of Episodic, Chronic and Refractory Migraine Management

Chaired by Paolo Martelletti
With Lars Edvinsson and Messoud Ashina

12th European Headache Federation Congress Springer Healthcare IME Symposium
Held on Friday 28th September, 2018, at Palazzo dei Congressi, Florence, Italy

Open the scientific summary
Includes presentation and video highlights from the expert faculty

At the end of the report try the quiz!

Watch Now: Faculty Interviews

   Welcome and introduction from Paolo Martelletti

Advances in the pathophysiology of migraine

    Lars Edvinsson  

New therapeutic options for episodic migraine

   Messoud Ashina 

Management of the chronic/refractory patient

  Paolo Martelletti


14:00 Welcome and introduction
Paolo Martelletti

14:05 Advances in the pathophysiology of migraine
Lars Edvinsson

14:20 New therapeutic options for episodic migraine
Messoud Ashina

14:35 Management of the chronic/refractory patient
Paolo Martelletti

14:50 Faculty discussion and audience questions

The Heralding a new era of episodic, chronic and refractory migraine management, Florence, Italy, 28/09/2019-28/09/2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

This programme is made possible thanks to independent educational sponsorship from Eli Lilly and Company.